Difference between revisions of "Pfizer"

From Powerbase
Jump to: navigation, search
(adding Business Insights firm)
(PR, Lobbying and Business Intelligence firms)
Line 99: Line 99:
 
Pfizer appears as a client for [[Rabin Strategic Partners]]<ref> Rabin Strategic Partners [http://www.rabinpartners.com/ Our Clients] Accessed 2nd January 2008</ref> (a full-service consultancy, public relations and communications agency).
 
Pfizer appears as a client for [[Rabin Strategic Partners]]<ref> Rabin Strategic Partners [http://www.rabinpartners.com/ Our Clients] Accessed 2nd January 2008</ref> (a full-service consultancy, public relations and communications agency).
  
In 2008, Pfizer is listed as a client for business intelligence firm [[Business Insights]]<ref> Business Insights [http://globalbusinessinsights.com/content/rbhc0019m.pdf Patient Power: The shift towards more informed, more powerful consumers of drugs] Accessed 5th February 2008</ref>
+
Pfizer is listed as a client for business intelligence firm [[Business Insights]]<ref> Business Insights [http://globalbusinessinsights.com/content/rbhc0019m.pdf Patient Power: The shift towards more informed, more powerful consumers of drugs] Accessed 5th February 2008</ref>
 +
 
 +
In 2008, Pfizer is listed as a client of [[Abbott Mead Vickers BBDO Ltd]]<ref>AMV BBDO [http://www.amvbbdo.com/ Clients] accessed 12th February 2008</ref>
  
 
==Patient Groups==
 
==Patient Groups==

Revision as of 16:33, 12 February 2008

Pfizer is one of the world's largest pharmaceutical companies. Based in the United States, it manufactures some of the most widely used prescription drugs in the world including Viagra.

Background and objectives

Pfizer was founded in 1849, it is in terms of revenue the largest Pharmaceutical company in the world, in 2004 it's revenues were over $50 billion. From the Pfizer website -

"Our basic role is to discover and develop medicines, help make medicines available, advance and share health information, and partner on public health programs." [1]


Overview

Market share/importance

Quoting from The Guardian in 2001, Corporate Watch report that:

‘There were times not long ago that drug companies were merely the size of nations. Now, after a frenzied two-year period of pharmaceutical mega-mergers, they are behemoths, which outweigh entire continents. The combined worth of the world’s top five drug companies is twice the combined GNP of all sub-Saharan Africa and their influence on the rules of world trade is many times stronger because they can bring their wealth to bear directly on the levers of western power.’[2]

Quoting from ‘Pfizer..not just bigger, but better’, a message by Pfizer CEO Henry A. McKinnell, Corporate Watch continues:

Pfizer is the largest and richest pharmaceutical enterprise in the world. Fortune® named Pfizer as the fifth-best ‘wealth-creator’ in America. The company is a global leader in human pharmaceuticals, and also has a large array of consumer health care, confectionery, and animal health care products. In 2000, its revenues equalled $29,6 billion (£20,14bn), eight of Pfizer’s pharmaceutical products attained sales of at least $1 billion (£680,4 million) each. Pfizer’s main competitors are Merck, GlaxoSmithKline, Novartis, Brystol Myers Squibb and AstraZeneca.
In 2001, Pfizer has budgeted approximately $5 billion (£3,402 bn) for research and development - more than any other drug company in the world. However, the company is likely to spend even more money on marketing. Extensive marketing practices (e.g. huge TV advertising campaigns) have turned some drugs, like Claritin and Viagra, into household names. According to the Financial Times (26 April 2001), ‘Pfizer has powered its way up the global ranking list to its unassailable position thanks mainly to its marketing prowess.’

History

The company was incorporated as Charles Pfizer & Co in the US in 1942 but the original business dates back to a partnership founded in 1849. Until the turn of the century this partnership produced only citric acid but then began to expand into other chemicals and pharmaceutical products. A phase of rapid growth began with the production of penicillin in World War II (it was Pfizer penicillin that arrived with the Allied forces on the beaches of Normandy in 1944) and the development of the company’s most famous product, the antibiotic Terramycin in 1949. Based on this strength, Pfizer grew in the 40s and 50s through horizontal integration in the US as well as through internal development.

Under the methodical directive of John Powers, head of international operations and future president and chief executive officer, Pfizer’s foreign market expanded into 100 countries and accounted for $175 million (£199 million) in sales by 1965. It would be years before any competitor came close to commanding a similar share of the foreign market. Pfizer’s 1965 worldwide sales figures of $220 million (£149,7 million) indicated that the company might possibly be the largest pharmaceutical manufacturer in the US. By 1980 Pfizer was one of the two US companies among the top ten pharmaceutical companies in Europe, and the largest foreign health care and agricultural product manufacturer in Asia. Powers guided the company in a new direction with an emphasis on research and development.

By 1989, Pfizer operated in more than 140 countries. Pfizer entered the 90s facing controversy about heart valves produced by Shiley, a Pfizer subsidiary. In 1990, 38 fractures of implanted valves were reported (see also crime section). Pfizer became a household name in the late 90s with its development of the break-through male impotence drug Viagra, which became the world’s fastest-selling pharmaceutical product (until overtaken by another Pfizer brand).

It appears Viagra also had an effect on the company’s senior executives; in 1999 they began forcing their intentions on rival Warner-Lambert, finally harassing the smaller company into a shotgun marriage in the first ever-hostile take-over in the pharma sector. This take-over turned Pfizer into the largest and richest pharmaceutical enterprise in the world.

Pfizer has worked its way up the global ranking list by way of internal growth and development, acquisitions, the licensing of products from competitors (Pfizer generously borrowed research from its competitors and released variants of these drugs. While all companies participated in this process of ‘molecular manipulation’, whereby a slight variance is produced in a given molecule to develop greater potency and decreased side effects in a drug, Pfizer was particularly adept at developing these drugs and aggressively seizing a share of the market), research & development, and by way of comprehensive marketing efforts.

Pfizer’s successful marketing efforts impinged on other companies in the pharma sector. (Pfizer’s modern market campaigns broke tradition in the pharma industry. Pfizer’s Terramycin campaign turned the company –a relative newcomer to the industry—into the largest advertiser in the American Medical Association’s journal. Some companies did not appreciate Pfizer’s ‘hard sell’ tactics and attacked Pfizer. However, after Pfizer’s campaign proved to be highly effective, other companies took a similar lead) It is manifested in the "arms race" of escalating numbers of sales representatives, particularly in the US; the huge pre-launch marketing budgets when companies try to make as big a splash as possible; and aggressive TV advertising campaigns in which drugs are seemingly being treated and presented to the consumer audience as any other consumer product.

Pfizer recently announced a new mission: to become the world’s ‘most valued’ company. Pfizer CEO McKinnell declared that the new mission came about because the old mission set in the 1990s (to lead the pharmaceutical industry) had been achieved. He explains: ‘Becoming most values simply means that we emerge as the company recognised as the best by patients, customers, business partners, and the communities where we live and work. It’s a long term mission focused on making Pfizer’s success a winning proposition for everyone.’[3] [4]

Bjork-Shiley heart valve

One of Pfizer's products, the Bjork-Shiley heart valve has been the subject of numerous lawsuits against the company. The heart valve was implanted in over 40,000 people between 1979 and 1986, however by the late 80's several cases of heart valve breakages began appearing. Worldwide around 600 breakages have been reported causing roughly 500 fatalities. The incident was all the more shocking as during testing in the 1970's several breakages were reported without the product ever being recalled, in fact several faulty valves were discovered by inspectors, superficially altered to make it appear they were safe and then implanted into patients. In 1994 Pfizer was found guilty of negligent practice and forced to pay around $200 million in damages over the incident. [1]

Resources

People

Pfizer affiliations

Pfizer provided generous support for the Expert Consensus Guideline Series: Treatment of Schizophrenia 1999 an initiative aiming at establishing uniform medication guidelines for schizophrenia[5]. It is reported that this was an initiative 'supported exclusively by 6 pharmaceutical companies: Eli Lilly and Company, Janssen Pharmaceutica Inc., Novartis Pharmaceuticals Corporation, Ortho-McNeil Pharmaceutical, Pfizer Inc. and Zeneca Pharmaceuticals' (now known as AstraZeneca). Michael Hogan and Laurie Flynn were also involved in this initiative.

PR, Lobbying and Business Intelligence firms

Pfizer appears as a client for Rabin Strategic Partners[6] (a full-service consultancy, public relations and communications agency).

Pfizer is listed as a client for business intelligence firm Business Insights[7]

In 2008, Pfizer is listed as a client of Abbott Mead Vickers BBDO Ltd[8]

Patient Groups

In 2006 Pfixer report that they gave funding to patient groups totalling £1,109,997.29[9]

The organisations receiving funding were...

In addition to the above patient group donations, Pfizer also financed the following organisations (December 2005 to November 2006) through its Pfizer UK Foundation [10]. The amount of grants given to all Pfizer UK Foundation projects in 2006 totalling £1,038,209:

External Links

References

  1. Pfizer Home Page Accessed 13th December 2007
  2. Corporate Watch Pfizer Inc Overview Accessed 13th December 2007
  3. Pfizer [www.pfizer.com/pfizerinc/investing/midyear/2001.pdf Pfizer’s first half year results 2001] Accessed 2006
  4. The Directory of Multinationals (1998) 'The World’s Top 500 Companies’. 5th edition, volume 2, Waterlow, Specialist Information Publishing Ltd.
  5. Weibert, S. The Genesis of President Bush’s New Freedom Commission on Mental Health Teenscreen Truth. Accessed 9th January 2008
  6. Rabin Strategic Partners Our Clients Accessed 2nd January 2008
  7. Business Insights Patient Power: The shift towards more informed, more powerful consumers of drugs Accessed 5th February 2008
  8. AMV BBDO Clients accessed 12th February 2008
  9. Pfizer Our Partnership With Patient Organisations Accessed 13th December 2007
  10. ibid